HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Masabumi Shibuya Selected Research

5- (3- (4- (octadecyloxy)phenyl)propionylamino)- 2,4'- oxydibenzoic acid

7/2004A novel low molecular weight VEGF receptor-binding antagonist, VGA1102, inhibits the function of VEGF and in vivo tumor growth.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Masabumi Shibuya Research Topics

Disease

47Neoplasms (Cancer)
10/2021 - 03/2002
17Inflammation (Inflammations)
01/2018 - 03/2002
11Pathologic Neovascularization
01/2014 - 12/2003
10Neoplasm Metastasis (Metastasis)
04/2010 - 10/2002
9Hypoxia (Hypoxemia)
11/2021 - 10/2004
6Pre-Eclampsia (Preeclampsia)
11/2021 - 11/2009
5Edema (Dropsy)
01/2016 - 02/2003
4Starvation
10/2019 - 12/2011
4Hemorrhage
05/2018 - 02/2003
4Ischemia
01/2015 - 03/2002
3Hypertension (High Blood Pressure)
10/2021 - 11/2009
3Ulcer
03/2019 - 09/2013
3Bone Diseases (Bone Disease)
01/2018 - 11/2006
3Breast Neoplasms (Breast Cancer)
01/2016 - 11/2007
3Wounds and Injuries (Trauma)
01/2016 - 03/2007
3Hyperplasia
11/2011 - 09/2006
3Carcinogenesis
07/2011 - 09/2005
3Ascites
03/2008 - 04/2002
2Endometriosis
08/2020 - 01/2019
2Choriocarcinoma
02/2020 - 01/2013
2Pain (Aches)
01/2020 - 06/2015
2Fibrosis (Cirrhosis)
09/2019 - 03/2015
2Stomach Ulcer (Gastric Ulcer)
03/2014 - 09/2013
2Macular Degeneration (Age-Related Maculopathy)
01/2014 - 06/2013
2Choroidal Neovascularization
06/2013 - 03/2008
2Osteosarcoma (Osteogenic Sarcoma)
05/2011 - 05/2009
2Leukemia
12/2009 - 08/2003
2Acute Myeloid Leukemia (Acute Myelogenous Leukemia)
12/2009 - 08/2003
2Glioma (Gliomas)
09/2009 - 09/2008
2Vascular Remodeling
02/2009 - 09/2003
2Rheumatoid Arthritis
04/2008 - 09/2006
2Atherosclerosis
04/2008 - 12/2007
2Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung)
07/2004 - 09/2002
2Lung Neoplasms (Lung Cancer)
09/2002 - 08/2002
2Ovarian Neoplasms (Ovarian Cancer)
06/2002 - 04/2002
1Cystic Lymphangioma (Hygroma)
11/2021
1Proteinuria
10/2021
1Low Back Pain (Lumbago)
01/2020
1Intervertebral Disc Degeneration
01/2020
1Pulmonary Fibrosis (Fibrosing Alveolitis)
09/2019

Drug/Important Bio-Agent (IBA)

55Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA
08/2020 - 03/2002
23Vascular Endothelial Growth Factor Receptor-1 (fms-Like Tyrosine Kinase)IBA
10/2021 - 10/2002
19Protein-Tyrosine Kinases (Tyrosine Kinase)IBA
09/2019 - 03/2002
11Vascular Endothelial Growth Factor Receptors (VEGF Receptors)IBA
08/2020 - 04/2002
10Proteins (Proteins, Gene)FDA Link
10/2021 - 04/2002
9Intercellular Signaling Peptides and Proteins (Growth Factors)IBA
02/2016 - 06/2002
8Vascular Endothelial Growth Factor Receptor-2 (Vascular Endothelial Growth Factor Receptor 2)IBA
01/2020 - 09/2003
8Vascular Endothelial Growth Factor BIBA
01/2016 - 09/2008
6Tyrosine (L-Tyrosine)FDA Link
11/2021 - 03/2006
6LigandsIBA
06/2015 - 11/2006
5Messenger RNA (mRNA)IBA
02/2020 - 12/2011
4Small Interfering RNA (siRNA)IBA
01/2020 - 12/2011
4Vascular Endothelial Growth Factor CIBA
01/2016 - 10/2004
4AntibodiesIBA
07/2011 - 09/2003
3Phosphotransferases (Kinase)IBA
10/2021 - 09/2006
3Biological ProductsIBA
01/2018 - 06/2002
3Fibroblast Growth Factor 2 (Basic Fibroblast Growth Factor)IBA
05/2013 - 03/2006
3Vascular Endothelial Growth FactorsIBA
01/2013 - 03/2008
3Receptor Protein-Tyrosine Kinases (Tyrosine Kinase Receptors)IBA
11/2010 - 08/2003
3Tyrosine Kinase InhibitorsIBA
03/2008 - 08/2003
3tivozanibIBA
03/2008 - 09/2006
2hydrogen sulfite (bisulfite)IBA
11/2021 - 02/2020
2Angiogenesis Inducing Agents (Angiogenesis Factor)IBA
02/2020 - 11/2018
2Becaplermin (PDGF-BB)FDA Link
05/2018 - 05/2011
2Pharmaceutical PreparationsIBA
11/2017 - 11/2009
2Vascular Endothelial Growth Factor DIBA
01/2016 - 06/2007
2CytokinesIBA
03/2015 - 05/2009
2Transcription Factors (Transcription Factor)IBA
03/2015 - 10/2004
2Acetic Acid (Vinegar)FDA LinkGeneric
03/2014 - 09/2013
2Neutralizing AntibodiesIBA
03/2014 - 04/2008
2Histone DemethylasesIBA
05/2013 - 12/2011
2Blocking AntibodiesIBA
01/2013 - 04/2010
2AngiopoietinsIBA
12/2011 - 10/2004
2Complementary DNA (cDNA)IBA
12/2011 - 04/2002
2Conditioned Culture MediaIBA
06/2011 - 08/2005
2Placenta Growth FactorIBA
10/2010 - 04/2010
2Angiogenesis InhibitorsIBA
09/2009 - 06/2005
2Macrophage Colony-Stimulating FactorIBA
05/2009 - 11/2006
2beta-hydroxyisovalerylshikoninIBA
02/2009 - 08/2002
2shikoninIBA
02/2009 - 08/2002
2HLA-A*02:01 antigenIBA
10/2006 - 06/2005
2Peptides (Polypeptides)IBA
10/2006 - 06/2005
2EpitopesIBA
10/2006 - 06/2005
2Chemokine CCL2 (Monocyte Chemoattractant Protein 1)IBA
12/2004 - 03/2002
2TIE-2 Receptor (Receptor, TIE 2)IBA
10/2004 - 09/2003
1Angiogenic ProteinsIBA
11/2021
1LuciferasesIBA
11/2021
1AmphiregulinIBA
11/2021
1A-Form DNA (A-DNA)IBA
02/2020
1DecitabineFDA Link
02/2020
1MethyltransferasesIBA
02/2020
1Dichlorodiphenyldichloroethane (DDD)IBA
01/2020
1phosphorylethanolamine (phosphoethanolamine)IBA
10/2019
1Glutamine (L-Glutamine)FDA Link
10/2019
1EnzymesIBA
10/2019
1phosphatidylethanolamineIBA
10/2019
1Transforming Growth Factors (Transforming Growth Factor)IBA
09/2019

Therapy/Procedure

17Therapeutics
01/2018 - 05/2004
4Transplantation
01/2016 - 03/2008
2Oral Administration
05/2011 - 11/2006